Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease Cyprium Therapeutics, a...

Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership...

Enwave to Expand Its Low-Carbon District Energy System East, Anchored by Menkes’s Landmark 100 Queens Quay East Development TORONTO, April 02, 2018 (GLOBE NEWSWIRE) -- Enwave Energy Corporation (“Enwave”), a leading provider of innovative, sustainable energy services, is pleased to announce district energy service...